非小细胞肺癌患者外周血CK19 mRNA的表达及与临床的关系

The Expression of Peripheral Blood CK19 mRNA in Patients with Non-small Cell Lung Cancer

目的:研究非小细胞肺癌(NSCLC)患者外周血中细胞角蛋白19(cytokeratin19,CK19)mRNA的表达变化及与临床的关系。方法:采用逆转录多聚酶链反应(RT-PCR)法进行外周血CK19mRNA表达的测定。结果:NSCLC组患者外周血CK19mRNA的阳性率为60.7%,显著高于良性病变组的3.3%和健康对照组的0(P<0.01);Ⅲ和Ⅳ期NSCLC患者的阳性率显著高于Ⅰ和Ⅱ期患者的阳性率(P<0.05);而不同病理类型NSCLC患者外周血CK19mRNA阳性率之间无显著性差异(P>0.05)。结论:外周血CK19mRNA的检测有助于我们对NSCLC患者的病情、预后和治疗进行判断,且这并不受病理分型的影响。

Objective： To detect the expression of cytokeratin 19 （CK19） mRNA in peripheral blood of patients with non-small cell lung cancer （NSCLC） and to examine the correlation between this expression and the clinical stage and pathological type. Methods： The expression of CK19 mRNA in peripheral blood was detected using reverse transcriptase polymerase chain reaction （RT-PCR）. Results： In the NSCLC group, the positive rate of CK19 mRNA in peripheral blood was 60.7%, which was significantly higher than the other two groups （P〈0.01）, and the level increased significantly as the clinical stage progressed （P〈0.05）. The positive rate of CK19 mRNA in different pathological types of NSCLC showed no significant difference （P〉0.05）. Conclusion： The detection of CK19 mRNA in peripheral blood is helpful for making a prognosis as well as to select the method of treatment in patients with NSCLC. The pathological type of NSCLC does not have any influence on CK19 expression.